According to AI News, on December 9th, Tianjing Biotechnology and Jichuan Pharmaceutical jointly announced that the biological product marketing application (BLA) for the treatment of children with growth hormone deficiency (PGHD) with Yitan long-acting recombinant human growth hormone injection (hereinafter referred to as "Yitan long-acting growth hormone") has been approved by NMPA.